GLSI — Greenwich Lifesciences Balance Sheet
0.000.00%
Last trade - 00:00
- $191.01m
- $185.50m
- 43
- 13
- 74
- 39
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.007 | 28.7 | 27.2 | 13.5 | 6.99 |
Total Current Assets | 0.007 | 28.7 | 27.2 | 13.5 | 6.99 |
Net Intangible Assets | |||||
Total Assets | 0.027 | 28.7 | 27.2 | 13.5 | 6.99 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 1.38 | 1.05 | 0.385 | 0.263 | 0.294 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 1.38 | 1.05 | 0.385 | 0.263 | 0.294 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -1.35 | 27.6 | 26.8 | 13.2 | 6.7 |
Total Liabilities & Shareholders' Equity | 0.027 | 28.7 | 27.2 | 13.5 | 6.99 |
Total Common Shares Outstanding |